jrnl2538

Publication Venue For

  • Gender, Professional Experiences, and Personal Characteristics of Academic Radiation Oncology Chairs: Data to Inform the Pipeline for the 21st Century.  104:979-986. 2019
  • Initial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience.  104:1091-1098. 2019
  • Pathologic Predictors of Local Recurrence in Atypical Meningiomas Following Gross Total Resection.  103:453-459. 2019
  • In Regard to Bossi et al.  102:669-670. 2018
  • Choosing Wisely at the End of Life: Use of Shorter Courses of Palliative Radiation Therapy for Bone Metastasis.  102:320-324. 2018
  • Post-mastectomy Radiation Yes but Internal Mammary Nodes No.  102:285-286. 2018
  • Objective Evaluation of a Didactic Curriculum for the Radiation Oncology Medical Student Clerkship.  101:1039-1045. 2018
  • Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer.  101:445-452. 2018
  • Qualitative Assessment of Academic Radiation Oncology Department Chairs' Insights on Diversity, Equity, and Inclusion: Progress, Challenges, and Future Aspirations.  101:30-45. 2018
  • American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology.  100:1057-1066. 2018
  • A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer.  100:595-605. 2018
  • Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative.  100:586-594. 2018
  • Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis.  100:606-617. 2018
  • Letter from Puerto Rico: The State of Radiation Oncology After Maria's Landfall.  99:1071-1072. 2017
  • An Integrated Real-time Monitored Liver SBRT Using Abdominal Compression.  99:E187-E187. 2017
  • Optimal Timing of Stereotactic Radiation Therapy Following Transarterial Chemoembolization for Locally Advanced Hepatocellular Carcinoma.  99:E144-E144. 2017
  • Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.  97:687-699. 2017
  • Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer.  97:362-371. 2017
  • The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.  96:1011-1020. 2016
  • Adherence to the Choosing Wisely Campaign Recommendations for Radiation Treatment Duration in Breast Cancer: Analysis of Medicare Data at 12 Centers in the Southeastern United States..  96:E5. 2016
  • An Automated Approach to High-Quality Single-Isocenter Volumetric Modulated Arc Therapy Stereotactic Radiosurgery Treatment Planning on a Linear Accelerator..  96:E618-E619. 2016
  • Analysis of Predictive Factors for Acute Esophagitis in Lung Cancer Radiation Therapy..  96:E193-E194. 2016
  • Analysis of Predictive Factors for Pneumonitis in Lung Cancer Radiation Therapy..  96:E482-E483. 2016
  • Coneless Linear Accelerator-Based Volumetric Modulated Arc Therapy Stereotactic Radiosurgery Technique for Functional Disorders..  96:E657-E658. 2016
  • Distant Brain Recurrence in Patients With 5 or More Newly Diagnosed Brain Metastases Treated With Stereotactic Radiosurgery (SRS) or Fractionated Stereotactic Radiation Therapy (FSRT) Alone..  96:E67. 2016
  • Intensity Modulated Radiation Therapy in Breast Cancer: Analysis of Medicare Data at 12 Institutions..  96:E6. 2016
  • Interinstitutional Dosimetric Comparison Between Stereotactic Radiosurgery and Volumetric Modulated Arc Therapy Radiosurgery for Difficult Intracranial Cases..  96:E693. 2016
  • Multi-Institutional Competing Risks Analysis Predicting Distant Brain Failure and Salvage Patterns After Upfront Radiosurgery Without Whole-Brain Radiation Therapy for Brain Metastasis..  96:S180-S181. 2016
  • Protocol RAD 0902: A Pilot Study of Transarterial Chemoembolization Followed by Stereotactic Radiation Therapy for Locally Advanced Hepatocellular Carcinoma..  96:S143. 2016
  • Stereotactic Hypofractionated Radiation Therapy for Intact Brain Metastases..  96:E120-E121. 2016
  • Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The┬áRTOG Experience.  95:1346-1354. 2016
  • Impending Challenges for the Use of Big Data.  95:890-894. 2016
  • Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined-modality therapy for muscle-invasive bladder cancer: A pooled analysis of NRG Oncology/RTOG 9906 and 0233.  94:67-74. 2016
  • Society of chairs of academic radiation oncology programs-endorsed radiation oncology department review process.  92:536-539. 2015
  • A phase 3 trial of 2 years of androgen suppression and radiation therapy with or without adjuvant chemotherapy for high-risk prostate cancer: Final results of radiation therapy oncology group phase 3 randomized trial NRG oncology RTOG 9902.  93:294-302. 2015
  • Posttraumatic stress disorder after high-dose-rate brachytherapy for cervical cancer: In regard to Kirchheiner et al.  90:468. 2014
  • Final results of local-regional control and late toxicity of rtog 9003: A randomized trial of altered fractionation radiation for locally advanced head and neck cancer.  89:13-20. 2014
  • Burnout in United States academic chairs of radiation oncology programs.  88:363-368. 2014
  • Combined treatment effects of radiation and immunotherapy: Studies in an autochthonous prostate cancer model.  87:769-776. 2013
  • Image guided radiation therapy (IGRT) technologies for radiation therapy localization and delivery.  87:33-45. 2013
  • In regard to Anscher.  85:1156. 2013
  • Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.  85:1275-1281. 2013
  • RTOG 0211: A phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.  85:1206-1211. 2013
  • In Regard to Yamamoto et al.  84:875-876. 2012
  • Image-based 3D treatment planning for vaginal cylinder brachytherapy: Dosimetric effects of bladder filling on organs at risk.  83:980-985. 2012
  • Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.  82:2111-2117. 2012
  • Reply to Drs. mulvenna and holt.  81:1194-1195. 2011
  • Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma.  81:331-338. 2011
  • Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer.  79:348-355. 2011
  • Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation.  77:1518-1526. 2010
  • Comparison of Methods to Reduce Dose to Swallowing-Related Structures in Head and Neck Cancer.  77:462-467. 2010
  • Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients.  77:655-661. 2010
  • RapidArc Radiation Therapy: First Year Experience at the University of Alabama at Birmingham.  77:932-941. 2010
  • Reduction of Dose Delivered to Organs at Risk in Prostate Cancer Patients via Image-Guided Radiation Therapy.  76:924-934. 2010
  • Dosimetric Factors Associated With Long-Term Dysphagia After Definitive Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.  76:403-409. 2010
  • Effects of Bladder Distension on Organs at Risk in 3D Image-Based Planning of Intracavitary Brachytherapy for Cervical Cancer.  76:485-489. 2010
  • Feasibility of Single-Isocenter Volumetric Modulated Arc Radiosurgery for Treatment of Multiple Brain Metastases.  76:296-302. 2010
  • Margin on Gross Tumor Volume and Risk of Local Recurrence in Head-and-Neck Cancer.  76:164-168. 2010
  • Beam's-Eye-View Dosimetrics-Guided Inverse Planning for Aperture-Modulated Arc Therapy.  75:1587-1595. 2009
  • In Reply to Drs. Larson and Sahgal.  75:316-317. 2009
  • Factors Associated With Long-Term Dysphagia After Definitive Radiotherapy for Locally Advanced Head-and-Neck Cancer.  73:410-415. 2009
  • In Reply to Dr. Speer.  72:1274. 2008
  • RLIP76 in Defense of Radiation Poisoning.  72:553-561. 2008
  • Conventional High-Dose-Rate Brachytherapy With Concomitant Complementary IMRT Boost: A Novel Approach for Improving Cervical Tumor Dose Coverage.  71:765-771. 2008
  • Locoregionally Advanced Head and Neck Cancer Treated With Primary Radiotherapy: A Comparison of the Addition of Cetuximab or Chemotherapy and the Impact of Protocol Treatment.  71:676-681. 2008
  • Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiotherapy in Postoperative Treatment of Endometrial and Cervical Cancer.  71:428-434. 2008
  • Enhancement of Glioma Radiotherapy and Chemotherapy Response With Targeted Antibody Therapy Against Death Receptor 5.  71:507-516. 2008
  • Differential Efficacy of Combined Therapy With Radiation and AEE788 in High and Low EGFR-Expressing Androgen-Independent Prostate Tumor Models.  71:237-246. 2008
  • Pretreatment Quality of Life Predicts for Locoregional Control in Head and Neck Cancer Patients: A Radiation Therapy Oncology Group Analysis.  70:353-360. 2008
  • Clofarabine Acts as Radiosensitizer In Vitro and In Vivo by Interfering With DNA Damage Response.  70:213-220. 2008
  • Predictors of Distant Brain Recurrence for Patients With Newly Diagnosed Brain Metastases Treated With Stereotactic Radiosurgery Alone.  70:181-186. 2008
  • In Reply To Dr. Heyman et al..  69:1650-1651. 2007
  • A Dosimetric Comparison of Electronic Compensation, Conventional Intensity Modulated Radiotherapy, and Tomotherapy in Patients With Early-Stage Carcinoma of the Left Breast.  68:1505-1511. 2007
  • Bevacizumab, Oxaliplatin, and Capecitabine With Radiation Therapy in Rectal Cancer: Phase I Trial Results.  68:472-478. 2007
  • A Phase II Multi-institutional Trial of Chemoradiation Using Weekly Docetaxel and Erythropoietin for High-Risk Postoperative Head and Neck Cancer Patients.  67:1323-1331. 2007
  • Inhibition of Survivin and Aurora B Kinase Sensitizes Mesothelioma Cells by Enhancing Mitotic Arrests.  67:1519-1525. 2007
  • Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.  66:1192-1198. 2006
  • Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.  66. 2006
  • Logistics of therapy with the ibritumomab tiuxetan regimen.  66. 2006
  • Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.  66. 2006
  • Overview of dosimetry for systemic targeted radionuclide therapy (STaRT).  66. 2006
  • Pretargeted radioimmunotherapy.  66. 2006
  • Summary of systemic targeted radionuclide therapy symposium.  66:S2. 2006
  • Systemic Targeted Radionuclide Therapy symposium introduction.  66. 2006
  • Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group protocol N0177.  65:1192-1199. 2006
  • Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.  62:97-103. 2005
  • A dynamic supraclavicular field-matching technique for head-and-neck cancer patients treated with IMRT.  60:959-972. 2004
  • Dose errors due to inhomogeneities in balloon catheter brachytherapy for breast cancer.  60:672-677. 2004
  • IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk.  60:505-512. 2004
  • Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.  59:943-951. 2004
  • Deformable image registration for the use of magnetic resonance spectroscopy in prostate treatment planning.  58:1577-1583. 2004
  • Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells.  58:950-958. 2004
  • Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression.  59:S2-S10. 2004
  • P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: A clinical/laboratory correlative analysis of RTOG-9003.  57:683-692. 2003
  • Bulb of penis as a marker for prostatic apex in external beam radiotherapy of prostate cancer.  56:1079-1084. 2003
  • Phase III quality-of-life study results: Impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer - RTOG 97-09.  56:832-836. 2003
  • An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma.  55:1037-1050. 2003
  • Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.  54:1180-1193. 2002
  • Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer.  54:370-378. 2002
  • A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer.  52:371-381. 2002
  • Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation..  54:921-927. 2002
  • RTOG 96-10: Reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck.  51:1299-1304. 2001
  • Long-term follow-up of RTOG 92-10: Cervical cancer with positive para-aortic lymph nodes.  51:982-987. 2001
  • Effect of Foley catheters on seed positions and urethral dose in 125I and 103Pd prostate implants.  49:1461-1468. 2001
  • Medical physics committee.  51:96-102. 2001
  • Radiation Therapy Oncology Group. Research Plan 2002-2006. Medical Physics Committee..  51:96-102. 2001
  • A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003.  48:7-16. 2000
  • A prospective evaluation of the timing of postoperative radiotherapy for preventing heterotopic ossification following traumatic acetabular fractures.  47:1347-1352. 2000
  • A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer.  47:939-944. 2000
  • 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: A multi-institutional review.  47:335-342. 2000
  • Effects of pelvic rotation and needle angle on pubic arch interference during transperineal prostate implants.  47:361-363. 2000
  • Patients with stage I non-small cell lung carcinoma at postoperative risk for local recurrence, distant metastasis, and death: Implications related to the design of clinical trials.  45:315-321. 1999
  • Patterns of failure and overall survival in patients with completely resected T3 N0 M0 non-small cell lung cancer.  45:91-95. 1999
  • Predictors of subclinical nodal involvement in clinical stages I and II non-small cell lung cancer: Implications in the inoperable and three- dimensional dose-escalation settings.  43:965-970. 1999
  • Ionizing radiation-induced MEK and Erk activation does not enhance survival of irradiated human squamous carcinoma cells.  42:921-925. 1998
  • Radiosensitization mediated by a transfected anti-ERBB-2 single-chain antibody in vitro and in vivo.  42:817-822. 1998
  • Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the radiation therapy oncology group 92-10.  41:817-822. 1998
  • Impact of beam energy and field margin on penumbra at lung tumor-lung parenchyma interfaces.  41:707-713. 1998
  • Adjuvant radiotherapy for squamous cell carcinoma of the tongue base: Improved local-regional disease control compared with surgery alone.  41:371-377. 1998
  • Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: A matched-pair analysis.  40:529-534. 1998
  • Spinal cord localization in the treatment of lung cancer: Use of radiographic landmarks.  40:347-351. 1998
  • Adenocarcinoma of the fallopian tube: Results of a multi-institutional retrospective analysis of 72 patients.  40:71-76. 1998
  • Postoperative localization of porta hepatis and abdominal vasculature in pancreatic malignancies: Implications for postoperative radiotherapy planning.  39:51-56. 1997
  • Quality assurance system to correct for errors arising from couch rotation in linac-based stereotactic radiosurgery.  38:883-890. 1997
  • Is comprehensive lymphatic irradiation for low-grade non-Hodgkin's lymphoma curative therapy? Long-term experience at a single institution.  38:3-8. 1997
  • Dynamics of pear-shaped dimensions and volume of intracavitary brachytherapy in cancer of the cervix: A desirable pear shape in the era of three-dimensional treatment planning.  37:1193-1199. 1997
  • Sucralfate for radiation mucositis: Results of a double-blind randomized trial.  37:275-279. 1997
  • Prolonged c-jun expression in irradiated ataxia telangiectasia fibroblasts.  36:355-360. 1996
  • Major geometric variations between intracavitary applications in carcinoma of the cervix: High dose rate vs. Low dose rate.  35:1035-1038. 1996
  • A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography.  35:165-172. 1996
  • Total lymphoid irradiation in the treatment of early or recurrent heart transplant rejection.  33:83-88. 1995
  • Twice-per-day fractionated high versus continuous low dose rate intracavitary therapy in the radical treatment of cervical cancer: A nonrandomized comparison of treatment results.  32:1425-1431. 1995
  • Conventional four-field pelvic radiotherapy technique without computed tomography-treatment planning in cancer of the cervix: Potential geographic miss and its impact on pelvic control.  31:109-112. 1995
  • The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities.  29:243-247. 1994
  • A clinically practical electron cone for the treatment of head and neck cancer.  28:1025-1028. 1994
  • Treatment of stage ie primary lymphoma of bone.  28:363-372. 1994
  • Malignant epidural spinal cord compression associated with a paravertebral mass: Its radiotherapeutic outcome on radiosensitivity.  27:1079-1083. 1993
  • Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts.  25:629-638. 1993
  • Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908).  22:545-548. 1992
  • Energy metabolism, pH changes, and lactate production in RIF-1 tumors following intratumoral injection of glucose.  22:95-101. 1992
  • Interaction of buthionine sulfoximine and the stabilization of DNA-topoisomerase II complexes by doxorubicin.  22:519-523. 1992
  • Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents.  22:549-551. 1992
  • Three-dimensional tumor dosimetry for radioimmunotherapy using serial autoradiography.  24:329-334. 1992
  • Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation.  22:1051-1056. 1992
  • A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck.  20:357-360. 1991
  • Expedient set-up of tangential breast fields with a simple gantry attachment.  21:1073-1083. 1991
  • A comparison of 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts.  18:1033-1041. 1990
  • Ferromagnetic thermoseeds: Suitable for an afterloading interstitial implant.  17:1341-1346. 1989
  • Protection of doxorubicin cytotoxicity by cycloheximide.  16:1209-1212. 1989
  • Radiation alone in the treatment of cancer of the uterine cervix: Analysis of pelvic failure and dose response relationship.  17:973-978. 1989
  • Adjuvant postoperative radiation therapy following radical hysterectomy in stage ib ca of the cervix-analysis of treatment failure.  14:445-449. 1988
  • Analysis of treatment modalities and their failures in stage IB cancer of the cervix.  15:831-835. 1988
  • Low-grade astrocytomas: Treatment results and prognostic variables.  15:837-841. 1988
  • Postoperative irradiation in stage IB carcinoma of cervix.  15:1257. 1988
  • 1986 Association of residents in radiation oncology survey.  13:1893-1895. 1987
  • Human leukemia cell binding and killing by anti-CD5 radioimmunotoxins.  13:1701-1712. 1987
  • Skeletal metastases from cancer of the uterine cervix: Frequency, patterns, and radiotherapeutic significance.  13:705-708. 1987
  • Use of ultrasound scan in prostatic I-125 implantation robert.  10:1971-1973. 1984
  • Hyperthermia with implanted electrodes: In vitro and in vivo correlations.  9:373-382. 1983
  • Southeastern cancer study group: Breast cancer studies 1972-1982.  9:1867-1874. 1983
  • Xeroderma pigmentosum in radiation oncology practice.  8:313. 1982
  • A practical system for clinical radiofrequency hyperthermia.  7:423-430. 1981
  • A randomized evaluation of adjunctive chemoimmunotherapy versus immunotherapy in patients with resected metastatic melanoma.  7:38-39. 1981
  • Cyclophosphamide/X-ray: Combined mode preparation for transplantation therapy.  5:1467-1470. 1979